See how you can guide the path her cancer takes
|
|
- Lynne Flowers
- 6 years ago
- Views:
Transcription
1 See how you can guide the path her cancer takes 1
2 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment in molecular pathology May 12-13, 2017 Naples 2
3 Biocartis: highlights MDx company founded in 2007, headquartered in Mechelen (Belgium), employing ~350 people Listed on Euronext (Brussels) Proprietary MDx system Idylla and diagnostic tests for oncology and infectious diseases Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics 3
4 Today, there are barriers for adoption of precision medicine 4
5 Molecular diagnostics complexity Blood/plasma Batch based processes Manual labour intensive Tissue (FFPE) Swabs Range of clinical specimen types Require high complexity lab infrastructure Require highly trained personnel Sputum Complexity of biomatrix Urine In oncology: sample volumes are small FNA s Limited Number of Labs and Increased TAT* to Physician and Patient Stool/feces * TaT: Turnaround Time 5
6 How can we improve access to high precision diagnostics? 6
7 Idylla features Accurate results at right sensitivity Console Fully automated sample-to-result Any clinical sample type* High levels of multiplexing Short turnaround time Modular and scalable Data connectivity Instrument *validated on FFPE and nasal swabs Disposable cartridge 7
8 Limitation of erroneous results due to standardized cartridge Any sample type* No sample pre-treatment All reagents on board No PCR lab infrastructure No cold chain Stable at room temperature *validated on FFPE and nasal swabs 8
9 High precision diagnostics for high precision medicine Biocartis ambition THERAPY SELECTION PATIENT MONITORING EARLY DIAGNOSIS Idylla Treatment guidance Companion diagnostics Monitoring of treatment progress Early detection of relapse Rapid diagnosis High sensitivity Comprehensive panels First time right molecular diagnostic system Combining advantages of point of care testing with quality of lab reference testing 9
10 Idylla FFPE tests on the market Oncology BRAF Test Melanoma Solid biopsy 1 FFPE tumor slice CE-IVD 7 mutations Sensitivity of 1% TaT* approx. 90 min KRAS Test Colorectal (CRC) Solid biopsy 1 FFPE tumor slice CE-IVD 21 mutations Sensitivity of 5% TaT* approx. 2 hours NRAS-BRAF Test Colorectal (CRC) Solid biopsy 1 FFPE tumor slice CE-IVD 23 mutations Sensitivity 5% TaT* approx. 2 hours EGFR Assay NSCLC Solid biopsy 1 FFPE tumor slice Research Use Only (RUO) 52 mutations Sensitivity of 1-5% TaT* approx. 2.5 hours Offering complete CRC mutation analysis o Follows most recent clinical guidelines o Opens routes towards faster treatment selection * TaT: Turnaround time RUO assays are not for sale in the USA Launch first test lung cancer menu with Idylla EGFR Mutation Assay RUO CE-IVD available in
11 Idylla ctdna tests on the market and in development Oncology ctbraf Assay Research Use Only (RUO) 7 mutations Sensitivity of < 1% TaT* approx. 85 min ctkras Assay Research Use Only (RUO) 21 mutations Sensitivity of 1-5% TaT* approx. 130 min ctnras-braf- S492R Assay Research Use Only (RUO) 23 mutations Sensitivity 5% TaT* 110 min ctegfr Assay Research Use Only (RUO) From DNA extracted from plasma Available end 2017 ctkras and ctnras First assay under Merck KGaA collaboration launched: Idylla ctkras and ctnras Assay 11
12 High performance in comparative studies Publication update 16 publications in key journals Key takeaways Superior sensitivity compared to competing NGS and qpcr technologies Unrivalled ease of use 5x KRAS 6x BRAF Shorter turnaround times By test 1x EGFR 4x ctbraf Flexibility towards different sample types* Suitable for both solid and liquid biopsies *validated on FFPE and nasal swabs * Janku et al. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther (2016) 15(6): 1 8; Schreuer et al. Quantitative assessment of BRAF V600 mutant cellfree tumor DNA from plasma as a diagnostic and therapeutic biomarker in patients with BRAF V600 mutant melanoma. ASCO 2015; De Biase et al. Fully Automated PCR detection of KRAS Mutations on Pancreatic Endoscopic Ultrasound Fine Needle Aspirates. J Clin Pathol 2016; Reijans et al. ESMO 2016, published on 6 October 2016; De Luca et al., J Clin Pathol 2016; J.L. Sherwood et al., KRAS ESMO Abstract 91 P: Implications of key differences across 12 KRAS mutation detection technologies and their relevance in clinical practice ; Ellen Vercauteren et al., NRAS ESMO Abstract 1175P: Ultra-rapid, sensitive, and fully automated extended RAS testing for metastatic colorectal cancer evaluation of an NRAS/BRAF/EGFR492 module ; Preliminary Performance Study based on Research data. Martin Reijans et al., EGFR ESMO Abstract 1173P: Fully automated and sensitive detection of EGFR exon 18, 19, 20 and 21 mutational status in less than 2.5 hours from a single FFPE slice ; Jérôme Solassol et al., Multi-Center Evaluation of the Fully Automated PCR-Based Idylla KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer 12
13 Outperforming reference testing Approx. 5% more patients could have benefited from targeted BRAF therapy BRAF Mutation Test KRAS Mutation Test STUDY/ TRIAL LOCATION # OF SAMPLES OVERALL CON- CORDANCE* OVERALL CONCORDANCE AFTER DISCORDANCE TEST** STUDY/ TRIAL LOCATION # OF SAMPLES OVERALL CON- CORDANCE + OVERALL CONCORDANCE AFTER DISCORDANCE TEST ++ Validation study Beta trial Research study Trial (off-label) Trial (off-label) Charité Berlin, UZA Antwerp 6 regional hospitals*** % 99.6% % 100% MD Anderson % 100% Medical University of Vienna Oxford University Hospitals NHS Trust % 100% % 100% Mini-performance evaluation (NGS) Verification study (Ultra Deep Seq) Verification study (alpha trial) Validation study Beta trials In-house % 100% In-house % 99.1% Commercial reference lab University Hospital Antwerp 12 european sites % 99.1% % 100% % 98.9% Outperforms reference testing in studies with 821 clinical samples (of which ~532 melanoma samples) * Reference methods: Roche cobas, CLIA laboratory PCR-based sequencing, Sequenom MassARRAY and Pyrosequencing ** Ultra deep sequencing and digital droplet PCR *** Rigshospital Copenhagen, Imelda Bonheiden, Jan Yperman Ieper, Hospital del Mar Barcelona, Karlsruhe, LabPON Hengelo Note: number samples tested with discordance test varies between study/trial Outperforms reference testing in studies with 850 clinical samples + Reference methods: Roche Cobas and NGS ++ Ultra deep sequencing and digital droplet PCR +++ Out of a subset of the discordant samples, insufficient sample was available to perform a discordance test 13
14 AstraZeneca study confirms high performance of Idylla KRAS Background Conclusions Comparative study organized by AstraZeneca Technology Overall sensivity Comparison of 12 different KRAS mutation detecting technologies: 5x NGS 3x qpcr 2x mass spec. 1x ddpcr 1x Sanger sequencing Focused on detection of KRAS mutations in lung cancer based on blinded samples Sensitivity Ease-of-use TaT** Idylla KRAS 96% Other qpcr (cobas/therascreen) 46-52% Mass-spectrometry 58-92% NGS % ddpcr 56% Sanger sequencing 0% Highest score for Idylla KRAS technology: o Lowest number of manual handling steps in sample preparation (1 to 2 steps versus 3 to > 20 steps) o Requires lowest level of expertise (1 versus 2-4 for others * ) Highest score for Idylla KRAS technology on total turnaround time (2 to 4 hours versus 1 day to 3 weeks) Source: poster by James L. Sherwood et al., presented at 2016 ESMO conference Copenhagen (Denmark) * One being the lowest level of expertise and four the highest ** TaT = total turnaround time 14
15 Idylla UK Neqas Scheme Idylla reported 100% correct results on FFPE samples in round 1 and 2 for BRAF in melanoma (CE), KRAS in colorectal cancer (CE), NRAS in colorectal cancer (RUO) and EGFR in lung cancer (RUO) 15
16 A Phase II clinical trial on the combination of dabrafenib plus trametinib for BRAF (+MEK)-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma Schreuer et al. Publication Lancet Oncology and Poster presented at ESMO Copenhagen 2016 AIM: Rechallenge BRAF V600mut melanoma patients who previously progressed on BRAF-inhibitors and immunotherapy with dabrafenib + trametinib (BRAF and MEK inhibitor) and this after treatment interruption. 25 patients (stage IV melanoma) PFS (progression free survival) 4,9 months 8 pts PR (32%) 10 pts SD (40%) (partial response) (stable disease) No mutant V600 ctbraf present 2 weeks after start rechallenge treatment Better PFS ctbraf levels could be an early indicator of outcome 16
17 Rapidly expanding test menu 17
18 Our Idylla menu Onco Solid Biopsy Onco Liquid Biopsy On market assay Idylla TM Retrieve CDx Infectious Area On market end Focus as from 2019 (indicative) Oncology Colorectal Lung Melanoma Other KRAS CE NRAS-BRAF CE NRAS/BRAF/EGFR492 RUO ctkras RUO EGFR RUO BRAF CE ctbraf RUO ctnras/braf/ EGFR492 RUO NRAS CE ctkras CE ctnras-braf CE EGFR CE ctegfr RUO MSI ctegfr CE GeneFusion Panel NGS Hotspot Panel Additional assays to be launched for CRC and lung cancer menus Expansion into major oncology areas: o Breast o Urology Colorectal o Immunotherapy o DNA repair* Additional NGS Prep Panels to be launched for number of pan-tumor indications CDx CDx signed Additional CDx programs to be added Infectious diseases IFV-RSV Panel CE + Ebola EUA IFV-RSV Panel 510k + Syndromic panels through partnership CE = CE-marked tests. RUO = Research Use Only. EUA = Emergency Use Authorization label + JnJ test Note: overview is subject to changes in prioritization of test development driven by several factors such as commercial and operational considerations. Overview excludes regional expansion, life cycle management and potential partner tests. 18
19 Unlocking the Power of High Precision Medicine for Every Patient
Idylla A fully automated, highly accurate, easy to use MDx platform: Too much to ask for?
GOING MOLECULAR HAS NEVER BEEN EASIER Idylla A fully automated, highly accurate, easy to use MDx platform: Too much to ask for? October 18 th, 2017 NOTICES AND WARNINGS This presentation has been prepared
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes The need for improved diagnostics At the advanced edge of oncology, rapid access to accurate data on disease state is vital. Current technologies such as
More informationLiquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System
Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System Erwin Sablon, Head of R&D, Biocartis NV World CDx, Boston, September 10 th 2015 0 About Biocartis Innovative molecular
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationY L L NOTHING BUT THIS. NOTHING IS SIMPLE IN ONCOLOGY.
ID Y L L NOTHING BUT THIS. A NOTHING IS SIMPLE IN ONCOLOGY. WHAT DOES IDYLLA TM M E AN FOR CANCER PATIENTS? High Precision Diagnostics for Personalized Medicine RAPID TREATMENT INITIATION 1 Test results
More informationBiocartis Corporate Presentation. September 2017
Biocartis Corporate Presentation September 2017 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of,
More informationBiocartis Corporate Presentation. November 2017
Biocartis Corporate Presentation November 2017 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of,
More informationGuide the path her cancer takes
Guide the path her cancer takes Direct access to same-day-results Fully Automated Molecular Diagnostics Fully Automated Molecular Diagnostics 24/7 FAST ACCURATE EASY ACCESSIBLE We at Biocartis aim to provide
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes Direct access to same-day-results Fully Automated Molecular Diagnostics 24/7 FAST ACCURATE EASY ACCESSIBLE We at Biocartis aim to provide direct access to
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes Direct access to same-day-results Fully automated Molecular Diagnostics www.biocartis.com We at Biocartis aim to provide direct access to personalized medicine
More informationBiocartis Corporate Presentation. April 2018
Biocartis Corporate Presentation April 2018 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and
More informationctbraf Mutation Assay
The first and only fully automated liquid biopsy assay ctbraf Idylla ctbraf Mutation Assay The easiest solution to implement liquid biopsy testing The potential of liquid biopsy The use of liquid biopsies
More informationNOTHING BUT THIS. NOTHING IS SIMPLE IN ONCOLOGY.
ID Y L L NOTHING BUT THIS. A NOTHING IS SIMPLE IN ONCOLOGY. Idylla TM A revolutionary, fully automated system that makes molecular testing convenient and exceptionally fast. Suitable for any lab. 2 Biocartis
More informationThe OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific
The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific Affairs,Sysmex 2 OncoBEAM liquid biopsy: circulating tumor DNA (ctdna)
More informationBiocartis Corporate Presentation. 3 December 2018
Biocartis Corporate Presentation 3 December 2018 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of,
More informationBiocartis Corporate Presentation. 7 January 2019
Biocartis Corporate Presentation 7 January 2019 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of,
More informationMUTATION TEST CE IVD. ctnras-braf FEATURES
ctnras-braf CE IVD TECHNICAL SHEET IDYLLA ctnras-braf MUTATION TEST The Idylla ctnras-braf Mutation Test, performed on the Biocartis Idylla System, is an in vitro diagnostic test for the qualitative detection
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationIntroduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory
Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free
More informationTransforming Oncology With Precision Medicine Solutions. Company Overview January 2017
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationHow close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience Dr Susan D. Richman, Dr Jennifer Fairley, Dr Rachel Butler, Dr Zandra C. Deans Overview Introduction to UK NEQAS
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationLa biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome
La biopsia liquida dei tumori: il viaggio Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome Must Know Necessary Travel Tips There is lack of drugs to treat all the
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationRobert Beer
Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free
More informationThe OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice
The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice Sysmex Inostics Dr. Friederike Lehmann Head of CRO Marketing Sysmex Corporation Kobe 2 Sysmex Corporation
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationLukas Bubendorf Pathologie. Liquid biopsies
Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationJefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationGuardant Health Investor Presentation. January 2019
Guardant Health Investor Presentation January 2019 Safe harbor statement This presentation contains forward-looking statements, which are statements related to future events that by their nature address
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationUtility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
More informationCLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases
CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases Adriana Muniz 1, Mariko Matsutani 1, Karena Kosco 1, John Spinosa 1, Cecile
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationBetter Cancer Monitoring with Circulating Tumor DNA. March 2016
Better Cancer Monitoring with Circulating Tumor DNA March 2016 Forward-Looking Statements Statements in this presentation about the Company's expectations, applications of its technology, markets, launch
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationValidation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D
Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Department of Radiation Oncology University of Florida College of Medicine Outline Objective
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationClinical molecular profiling to detect targetable alterations in archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease
ECD International Medical Symposium Paris, France September 15, 2016 Clinical molecular profiling to detect targetable alterations in archival tumor tissue and cell-free DNA from patients with Erdheim-Chester
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationTransforming Oncology With Precision Cancer Therapeutics. Company Overview January 2017
Transforming Oncology With Precision Cancer Therapeutics Company Overview January 2017 COMPANY OVERVIEW JUNE 2017 Forward-Looking Statements Certain statements in this presentation are forward-looking
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationQIAGEN's Growing Immuno-Oncology Testing Portfolio
QIAGEN's Growing Immuno-Oncology Testing Portfolio QIAGEN Your Partner in Translational Medicine Current Biomarkers of Immuno-Oncology Focus: Immuno-Oncology Testing Portfolio Tumor mutation burden (TMB)
More informationDisclosures. Molecular Cytopathology. Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block. Molecular Cytopathology Solid Tumor
Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block Disclosures None relevant to this talks Dara L. Aisner, M.D., Ph.D. Assistant Professor Co-Director, Colorado Molecular Correlates
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationAn innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution
An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution James H. Godsey, Ph.D. Vice President, Research & Development Clinical Sequencing Division (CSD) Life
More informationCepheid: Delivering a Better Way
Cepheid: Delivering a Better Way Dieneke Brockmans March 14, 2017 1 Cepheid Our Mission Delivering a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere.
More informationQA in Predic+ve Molecular Pathology. Anders Edsjö Uppsala
QA in Predic+ve Molecular Pathology Anders Edsjö Uppsala 2012-09- 25 QA in Predic+ve Molecular Pathology Why? What? How? Results Future? Predic+ve Molecular Pathology Predictive Molecular Pathology - Need
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationWe Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016 1 Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA
More informationDelivering on the Promise of Personalised Healthcare
Delivering on the Promise of Personalised Healthcare Dr John S Mills Diagnostic Team Director, Personalised Healthcare and Biomarkers Function, AstraZeneca, UK EBF 6 th Open Symposium, Barcelona, 20 Nov
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationWat is de potentiële waarde van ctdna? PLCRC - MEDOCC
Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?
More informationPlasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc)
Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc) Authors: Andrea Petricca Mancuso, Veronica Varchetta, Fabrizio
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationEnterprise Interest No
Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationCompanion & Complementary Diagnostics: Clinical and Regulatory Perspectives
Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives Workshop on Companion Diagnostics January 31, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute Fredensborg, Denmark
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationIntroduction to liquid biopsy in a Specialized Cancer Center
Introduction to liquid biopsy in a Specialized Cancer Center Dr. Antonio Cubillo Head, Medical OncologyDepartment HM-CIOCC In collaboration with OUTLINE Need Liquid Biopsy: Definition and techniques Sensitivity
More informationOverview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories
Overview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories Dr. Nils t Hart University Medical Center Groningen, The Netherlands Drs. Cleo Keppens Catholic University of Leuven, Belgium
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationClinical Utility of Droplet ddpcr, moving to diagnostics. Koen De Gelas, PhD, CRIG ddpcr mini symposium, 15/05/2018
1 Clinical Utility of Droplet ddpcr, moving to diagnostics 2 Koen De Gelas, PhD, CRIG ddpcr mini symposium, 15/05/2018 Disclaimer Disclaimer: all consumables, instruments, applications and software covered
More informationLearning from the Impact of the Drug-Diagnostics Strategy in Oncology
Learning from the Impact of the Drug-Diagnostics Strategy in Oncology Critical Path to TB Drug Regimens 2017 Workshop Washington DC March 22, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute
More informationThe Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw
The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw Introduction The CRUK Stratified Medicine Programme: SMP1 rationale, design and implementation The role of the cellular
More informationMARCH 2017 RESEARCH REPORT
1 MARCH 2017 RESEARCH REPORT LIQUID BIOPSY MARKETS by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides Liquid Biopsy
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationCirculating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications
Circulating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications Martin Schlumpberger, Ass.Director R&D, QIAGEN GmbH IQNpath 2017 - Circulating
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More information